Skip Content
 
Page Banner Image

SHIELD HD

Triplet Therapeutics has developed the SHIELD HD natural history study for Huntington disease (HD), which recently enrolled its first patients. The study will include about 60 HD gene carriers – both pre-manifest and early manifest individuals – and is intended to inform future clinical trials.

If you’re not familiar with Triplet’s therapeutic approach, it’s different from other therapies currently entering the HD clinic, in that it targets a newly discovered set of modifiers for HD instead of the HTT gene. Operating “upstream” means that Triplet may be able to treat the disease very early — an approach that could preserve neuronal function and halt neurodegeneration.

The study is registered at ClinicalTrials.gov (Note: ClinicalTrials.gov  lists only the first open site, but there will be more – currently the plan is for 2 sites in Canada.)

You can see the full press release online here.

Status: Currently recruiting.

Study Type: Observational

Canadian Locations:

Ontario

Location: Centre for Movement Disorders, Toronto
1 Valleybrook Drive
Suite 400
Toronto, ON  M3B 2S7

Coordinator: Libby Kalman
Phone: 416-847-7084


We support those facing huntington disease
 Latest Blog
 Questions

Questions

Let Us Know How We Can Help
Enter your name, email address and question(s) below for assistance.

 Connect
 Newsletter

Newsletter

Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up